



Biocon Limited
20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

www.biocon.com

May 23, 2023

To, The Manager BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To, The Manager National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050
Scrip Code - 532523	Scrip Symbol – Biocon

Subject: Disclosure of Related Party Transactions pursuant to Regulation 23(9) of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 ('SEBI Listing Regulation').

Dear Sir/Madam,

In Compliance with Regulation 23(9) of SEBI Listing Regulations, please find enclosed disclosure of related party transactions on consolidated basis for the half year ended March 31, 2023, drawn in accordance with applicable accounting standard.

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the above information on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

MAYANK
K
VERMA
Digitally signed
by MAYANK
VERMA
Date: 2023.05.23
23:17:30 +05'30'

Mayank Verma
Company Secretary & Compliance Officer
Membership No.: ACS 18776

Enclosed: As above

190	Biocon Biologics Limited	XXXXXXXXXX	Biocon Academy	XXXXXXXXXX	Fellow subsidiary	Any other transaction	Expenses incurred on behalf of the related party	11	8											
191	Biocon Biologics Limited	XXXXXXXXXX	Biocon Academy	XXXXXXXXXX	Fellow subsidiary	Any other transaction	Trade and other receivables													
192	Biocon Biologics UK Limited	XXXXXXXXXX	Biocon Pharma UK Limited	XXXXXXXXXX	Fellow subsidiary	Any other transaction	Reimbursement of expense	NA	0											
193	Biocon Biologics UK Limited	XXXXXXXXXX	Biocon Pharma UK Limited	XXXXXXXXXX	Fellow subsidiary	Any other transaction	Trade and other payables													
194	Biocon Biologics UK Limited	XXXXXXXXXX	Biocon Biologics Brasil Ltda	XXXXXXXXXX	Wholly owned subsidiary	Purchase of goods or services	Purchase of goods or services	NA	48											
195	Biocon Biologics UK Limited	XXXXXXXXXX	Biocon Biologics Brasil Ltda	XXXXXXXXXX	Wholly owned subsidiary	Any other transaction	Trade and other payables													
196	Biocon Biologics UK Limited	XXXXXXXXXX	Biocon Biologics Inc	XXXXXXXXXX	Wholly owned subsidiary	Purchase of goods or services	Purchase of goods or services	NA	289											
197	Biocon Biologics UK Limited	XXXXXXXXXX	Biocon Biologics Inc	XXXXXXXXXX	Wholly owned subsidiary	Any other transaction	Trade and other payables													
198	Biocon Biologics UK Limited	XXXXXXXXXX	Biocon Biologics FZ LLC	XXXXXXXXXX	Wholly owned subsidiary	Purchase of goods or services	Purchase of goods or services	NA	86											
199	Biocon Biologics UK Limited	XXXXXXXXXX	Biocon Biologics FZ LLC	XXXXXXXXXX	Wholly owned subsidiary	Any other transaction	Trade and other payables													
200	Biocon Biologics UK Limited	XXXXXXXXXX	Biosimilars NewCo Limited	XXXXXXXXXX	Subsidiary	Purchase of goods or services	Purchase of goods or services	NA	1,738											
201	Biocon Biologics UK Limited	XXXXXXXXXX	Biosimilars NewCo Limited	XXXXXXXXXX	Subsidiary	Any other transaction	Profit share exp	NA	227											
202	Biocon Biologics UK Limited	XXXXXXXXXX	Biosimilars NewCo Limited	XXXXXXXXXX	Subsidiary	Any other transaction	Profit share income	NA	1,111											
203	Biocon Biologics UK Limited	XXXXXXXXXX	Biosimilars NewCo Limited	XXXXXXXXXX	Subsidiary	Sale of goods or services	Sale of goods or services	NA	2,503											
204	Biocon Biologics UK Limited	XXXXXXXXXX	Biosimilars NewCo Limited	XXXXXXXXXX	Subsidiary	Investment	Investment	NA	17,333				No indebtedness	NA	NA	Equity shares	NA	NA	NA	For acquiring Biosimilars business from Viatris Inc
205	Biocon Biologics UK Limited	XXXXXXXXXX	Biosimilars NewCo Limited	XXXXXXXXXX	Subsidiary	Any other transaction	Guarantee given	NA	98,616											
206	Biocon Biologics UK Limited	XXXXXXXXXX	Biosimilars NewCo Limited	XXXXXXXXXX	Subsidiary	Any other transaction	Trade and other receivables													
207	Biocon Biologics UK Limited	XXXXXXXXXX	Biosimilars NewCo Limited	XXXXXXXXXX	Subsidiary	Any other transaction	Guarantee outstanding													
208	Biocon Biologics UK Limited	XXXXXXXXXX	Biosimilar Collaborations Ireland Limited	XXXXXXXXXX	Wholly owned subsidiary	Any other transaction	Profit share income	NA	1,023											
209	Biocon Biologics UK Limited	XXXXXXXXXX	Biosimilar Collaborations Ireland Limited	XXXXXXXXXX	Wholly owned subsidiary	Purchase of goods or services	Purchase of goods or services	NA	418											
210	Biocon Biologics UK Limited	XXXXXXXXXX	Biosimilar Collaborations Ireland Limited	XXXXXXXXXX	Wholly owned subsidiary	Investment	Investment	NA	48,075				No indebtedness	NA	NA	Equity shares	NA	NA	NA	For acquiring Biosimilars business from Viatris Inc
211	Biocon Biologics UK Limited	XXXXXXXXXX	Biosimilar Collaborations Ireland Limited	XXXXXXXXXX	Wholly owned subsidiary	Any other transaction	Trade and other receivables													
212	Biocon SDN BHD	XXXXXXXXXX	Biocon Biologics FZ LLC	XXXXXXXXXX	Fellow subsidiary	Purchase of goods or services	Purchase of goods or services	NA	13											
213	Biocon SDN BHD	XXXXXXXXXX	Biocon Biologics FZ LLC	XXXXXXXXXX	Fellow subsidiary	Any other transaction	Trade and other payables													
214	Biocon SDN BHD	XXXXXXXXXX	Biosimilars NewCo Limited	XXXXXXXXXX	Fellow subsidiary	Purchase of goods or services	Purchase of goods or services	NA	46											
215	Biocon SDN BHD	XXXXXXXXXX	Biosimilars NewCo Limited	XXXXXXXXXX	Fellow subsidiary	Sale of goods or services	Sale of goods or services	NA	110											
216	Biocon SDN BHD	XXXXXXXXXX	Biosimilars NewCo Limited	XXXXXXXXXX	Fellow subsidiary	Sale of goods or services	Sale of goods or services	NA	23											
217	Biocon SDN BHD	XXXXXXXXXX	Biosimilars NewCo Limited	XXXXXXXXXX	Fellow subsidiary	Any other transaction	Expense recovery	NA	154											
218	Biocon SDN BHD	XXXXXXXXXX	Biosimilars NewCo Limited	XXXXXXXXXX	Fellow subsidiary	Any other transaction	Profit share income	NA	1,129											
219	Biocon SDN BHD	XXXXXXXXXX	Biosimilars NewCo Limited	XXXXXXXXXX	Fellow subsidiary	Any other transaction	Guarantee given	NA	98,616											
220	Biocon SDN BHD	XXXXXXXXXX	Biosimilars NewCo Limited	XXXXXXXXXX	Fellow subsidiary	Any other transaction	Trade and other receivables													
221	Biocon SDN BHD	XXXXXXXXXX	Biosimilars NewCo Limited	XXXXXXXXXX	Fellow subsidiary	Any other transaction	Guarantee outstanding													
222	Biocon SDN BHD	XXXXXXXXXX	Biosimilar Collaborations Ireland Limited	XXXXXXXXXX	Fellow subsidiary	Any other transaction	Expense recovery	NA	13											
223	Biocon SDN BHD	XXXXXXXXXX	Biosimilar Collaborations Ireland Limited	XXXXXXXXXX	Fellow subsidiary	Any other transaction	Trade and other receivables													
224	Biocon Biologics FZ LLC	XXXXXXXXXX	Biocon FZ LLC	XXXXXXXXXX	Fellow subsidiary	Any other transaction	Expenses incurred by related party on behalf of the Company	NA	1											
225	Biocon Biologics FZ LLC	XXXXXXXXXX	Biocon FZ LLC	XXXXXXXXXX	Fellow subsidiary	Any other transaction	Trade and other payables													
226	Biosimilar Collaborations Ireland Limited	XXXXXXXXXX	Mylan Inc	XXXXXXXXXX	Other related party	Any other transaction	Reimbursement of expense	551	551											
227	Biosimilar Collaborations Ireland Limited	XXXXXXXXXX	Mylan Inc	XXXXXXXXXX	Other related party	Any other transaction	Trade and other payables													
228	Biosimilar Collaborations Ireland Limited	XXXXXXXXXX	Biosimilars NewCo Limited	XXXXXXXXXX	Fellow subsidiary	Any other transaction	Reimbursement of expense													
229	Biosimilar Collaborations Ireland Limited	XXXXXXXXXX	Biosimilars NewCo Limited	XXXXXXXXXX	Fellow subsidiary	Any other transaction	Trade and other payables													

Note:

- Share-based compensation expense allocable to key management personnel is INR 37 which is not included in the remuneration disclosed above for Biocon Limited.
- The remuneration to key managerial personnel does not include the provisions made for gratuity and compensated absences, as they are obtained on an actuarial basis for the Company as a whole.
- The above does not include allowance for expected credit loss amounting to Rs. 397 towards receivable from associate company.

* Amounts are not presented since the amounts are rounded off to Rupees million.